Semaglutide
semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist that produces 10-15% body weight loss, meaningful HbA1c reduction, and a 20% reduction in major cardiovascular events in overweight adults with established cardiovascular disease. Once weekly subcutaneous injection.
GLP-1 receptor agonistPrescription requiredEvidence A
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.
Why it matters
Semaglutide is the most studied GLP-1 in the world and has reshaped the treatment of obesity and metabolic disease. STEP 1 (NEJM 2021, Wilding) demonstrated 14.9% weight loss at 68 weeks in adults with obesity — a magnitude previously achievable only with bariatric surgery. SUSTAIN-6 (NEJM 2016) showed a 26% reduction in major adverse cardiovascular events in diabetics. The SELECT trial (NEJM 2023, Lincoff) extended this benefit to non-diabetic obesity, demonstrating a 20% relative risk reduction in cardiovascular death, MI, or stroke over 3.3 years — the first time a weight-loss drug has shown hard cardiovascular outcome benefit in non-diabetic patients. Beyond glycemia and weight, semaglutide reduces hepatic steatosis (NEJM 2021, Newsome), lowers ApoB and triglycerides, and shows early signal in alcohol use disorder and Alzheimer disease. For high-performance men with metabolic syndrome, visceral adiposity, elevated ApoB, or NAFLD on imaging, semaglutide is the most potent pharmacologic lever currently available — provided lean mass is protected through resistance training and adequate protein.
Uses
Label uses (approved)
- Type 2 diabetes mellitus (Ozempic, Rybelsus)
- Chronic weight management (Wegovy, BMI >=30 or >=27 with comorbidity)
- Cardiovascular risk reduction in overweight/obese adults with established CVD (Wegovy)
Off-label (educational only)
- Metabolic syndrome without obesity — Improves insulin sensitivity, visceral adiposity, and hepatic steatosismoderate
- NAFLD / MASH — Phase 2/3 data show significant liver fat reductionmoderate
- Alcohol use disorder — Emerging RCT data on craving reductionweak
Dosing
Label dose
Wegovy: 0.25 mg weekly x4w → 0.5 mg x4w → 1.0 mg x4w → 1.7 mg x4w → 2.4 mg weekly maintenance. Ozempic: 0.25 → 0.5 → 1.0 → 2.0 mg weekly
Off-label / biohacker dose
Many users plateau and maintain at 0.5-1.0 mg weekly rather than maximum dose
Titration: Strictly follow 4-week titration steps to minimize nausea. Do not skip steps. If side effects are severe at a given dose, hold that dose another 4 weeks before escalating. Maintenance dose should be the lowest dose that delivers acceptable weight and metabolic response.
When to take: Weekly subcutaneous injection on the same day each week, any time of day, with or without food. Rotate injection sites.
Side effects & warnings
Common
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Decreased appetite
- Fatigue
- Headache
- Injection site reactions
Uncommon but serious
- Cholelithiasis (1-2% per year)
- Acute pancreatitis (rare, <1%)
- Sarcopenia / accelerated lean mass loss
- Gastroparesis-like symptoms
- Hair shedding (telogen effluvium during rapid weight loss)
Serious warnings
Boxed warning for medullary thyroid carcinoma based on rodent data — avoid in personal or family history of MTC or MEN2. Acute pancreatitis is rare but well-documented; discontinue immediately if suspected. Severe gastroparesis can occur and complicates anesthesia (stop 1-2 weeks before elective surgery per ASA guidance). Lean mass loss can reach 25-40% of total weight loss without resistance training and adequate protein — this is the single biggest under-counseled risk for performance-focused users. Diabetic retinopathy can transiently worsen with rapid glycemic correction.
Biomarkers affected
apob
decreaseMeaningful ApoB reduction in STEP and SELECT secondary analyses
Evidence: moderate
blood pressure
decreaseSystolic BP reduction of 5-7 mmHg in STEP trials
Evidence: strong
fasting glucose
decreaseSubstantial reductions via enhanced glucose-dependent insulin secretion and glucagon suppression
Evidence: strong
fasting insulin
decreaseImproved insulin sensitivity after weight loss; lower fasting insulin demand
Evidence: strong
hba1c
decreaseReduces HbA1c by 1.5-2.0% (SUSTAIN program)
Evidence: strong
homa ir
decreaseMajor improvements in insulin resistance with weight loss
Evidence: strong
hscrp
decreaseSubstantial reductions in inflammation markers in SELECT
Evidence: moderate
ldl c
decreaseModest LDL reductions accompany weight loss
Evidence: moderate
triglycerides
decreaseReductions of 15-25% (STEP, SELECT)
Evidence: strong
Monitoring
Baseline and periodic HbA1c, lipid panel, ALT/AST (especially in NAFLD), thyroid exam, body composition (DEXA recommended for performance users)
The honest risk picture
## What can go wrong
**Nausea and GI side effects** are universal during titration. About 40% of users experience nausea; vomiting and diarrhea are common. Strict adherence to 4-week titration steps and small, low-fat meals helps. Most users adapt within 2-3 weeks at each dose.
**Lean mass loss** is the single largest risk for performance-focused men. Without resistance training and 1.6-2.0 g/kg/day protein, 25-40% of total weight loss is lean tissue. This means losing 15 kg can mean losing 4-6 kg of muscle. DEXA-monitored programs and strength training are non-negotiable for athletes.
**Gallstones** form in 1-2% of users per year, driven by rapid weight loss rather than the drug itself.
**Pancreatitis** is rare (~1 per 1000) but serious. Persistent severe abdominal pain warrants immediate evaluation.
**Gastroparesis** complicates anesthesia and elective surgery; ASA recommends holding GLP-1s 1-2 weeks before procedures.
**Rebound weight gain** after discontinuation is the rule, not the exception. STEP 4 showed two-thirds of lost weight returned within a year. This is a chronic-use medication for most.
**Boxed warning** for medullary thyroid carcinoma in rodents; contraindicated in MEN2 and personal/family MTC history.
Practical context
Cost (US, retail)
$900/mo
Legality
Prescription-only globally. Compounded semaglutide widely available in US gray market; FDA action ongoing.
Interactions
true
FAQ
How much weight will I lose on semaglutide?+
STEP 1 showed average 14.9% body weight loss at 68 weeks on 2.4 mg weekly versus 2.4% on placebo. Real-world results are typically 10-15% over 12-18 months.
Will I lose muscle?+
Yes — up to 25-40% of total weight loss is lean mass without intervention. Resistance training 2-3x weekly and 1.6-2.0 g/kg protein intake substantially reduce this loss.
What happens when I stop semaglutide?+
STEP 4 showed two-thirds of weight is regained within a year of discontinuation. Most users require either indefinite treatment, a maintenance dose, or aggressive lifestyle change to sustain results.
Is compounded semaglutide safe?+
Quality varies widely. FDA has issued multiple warnings about adulterated and mislabeled compounded GLP-1s. Only use 503A/503B compounders with verifiable testing if pursuing this route.
Can I drink alcohol on semaglutide?+
Yes, but tolerance often drops sharply. Many users report aversion to alcohol — possibly mediated by central GLP-1 receptors involved in reward.
References (4)+
- STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al). NEJM 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
- SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (Lincoff et al). NEJM 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/
- SUSTAIN-6: Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (Marso et al). NEJM 2016. https://pubmed.ncbi.nlm.nih.gov/27633186/
- Semaglutide in NASH: phase 2 trial (Newsome et al). NEJM 2021. https://pubmed.ncbi.nlm.nih.gov/33185364/
The prime report
Weekly performance intelligence.
New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.